Katherine has close to 4 years of experience working for two Canadian public payers where she built extensive knowledge regarding public drug plans as well as the interplay with the overall pharmaceutical landscape. Her roles in both New Brunswick and Alberta supported public payer decision making and she was an active participant in pan-Canadian Pharmaceutical Alliance (pCPA) operations. She has led and supported numerous pCPA negotiations and subsequent product listing agreement implementation in both provinces. She was integral to the development and implementation of multiple policy initiatives, including the Alberta Biosimilar Initiative. Katherine’s background in economics, along with her experience with two public drug plans and the pCPA provide a unique and valuable perspective when working towards market access solutions.